The FDA has approved pirtobrutinib for the treatment of adult patients with previously untreated CLL or SLL harboring no known 17p deletion.
News|Articles|December 5, 2025
Inside the Most Anticipated CLL Abstracts: What to Expect From ASH 2025
Author(s)Kyle Doherty
Fact checked by: Ashling Wahner
Ahead of the 2025 ASH Annual Meeting, OncLive spoke with experts in CLL care to preview the most anticipated meeting abstracts.
Advertisement
Advertisement
With the upcoming
Related to this article
The NMPA has approved of pirtobrutinib in treatment-naive and previously treated CLL/SLL.
The top 5 OncLive TV videos of the week cover insights in breast cancer, PV, myeloma, and CLL.
Mary Ann Anderson, MBBS, FRACP, FRCPA, PhD, discusses recent CLL approvals, BTK and BCL-2 inhibitor safety, and individualizing frontline therapy.
By finding a way to attack the most important human oncogene, KRAS, the UCSF chemical biologist launched a new era in cancer treatment.
TRE-515 earned fast track status in combination with KRAS inhibitors for G12C-mutated NSCLC after anti–PD-(L)1 therapy and platinum-based chemotherapy.
An NDA for zipalertinib in EGFR exon 20 insertion–positive NSCLC is being supported by phase 3 REZILIENT3 data.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Advertisement
Advertisement